Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Newell

Showing results (441-450 of 519) with videos related to

Pageof 52
Sort By:
Leukemia Research|February 15, 2011
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myelomaLuis R de Brito, Mike A Batey, Yan Zhao, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidoneP A Speth, M E Gore, A J Pateman, et al.
Journal of the National Cancer Institute|May 8, 2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337Paula Wells, Eric Aboagye, Roger N Gunn, et al.
Journal of the American Chemical Society|May 4, 2006
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope eliminationRoger J Griffin, Andrew Henderson, Nicola J Curtin, et al.
Journal of Medicinal Chemistry|October 1, 1985
Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituentT R Jones, A H Calvert, A L Jackman, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717)A H Calvert, D R Newell, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717A H Calvert, D L Alison, S J Harland, et al.
Chemical Science|June 30, 2017
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatasesTristan Reuillon, Sari F Alhasan, Gary S Beale, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2000
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)H C Barlow, K J Bowman, N J Curtin, et al.
Epilepsy Research|October 1, 1994
Do dichotic word listening asymmetries predict side of temporal lobe seizure onset?G P Lee, D W Loring, N R Varney, et al.
Pageof 52

Showing results (441-450 of 519) with videos related to

Sort By:
Pageof 52
Leukemia Research|February 15, 2011
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myelomaLuis R de Brito, Mike A Batey, Yan Zhao, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidoneP A Speth, M E Gore, A J Pateman, et al.
Journal of the National Cancer Institute|May 8, 2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337Paula Wells, Eric Aboagye, Roger N Gunn, et al.
Journal of the American Chemical Society|May 4, 2006
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope eliminationRoger J Griffin, Andrew Henderson, Nicola J Curtin, et al.
Journal of Medicinal Chemistry|October 1, 1985
Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituentT R Jones, A H Calvert, A L Jackman, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717)A H Calvert, D R Newell, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717A H Calvert, D L Alison, S J Harland, et al.
Chemical Science|June 30, 2017
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatasesTristan Reuillon, Sari F Alhasan, Gary S Beale, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2000
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)H C Barlow, K J Bowman, N J Curtin, et al.
Epilepsy Research|October 1, 1994
Do dichotic word listening asymmetries predict side of temporal lobe seizure onset?G P Lee, D W Loring, N R Varney, et al.
Pageof 52